CN116322662A - 用于治疗或预防与β冠状病毒感染相关的疾病的组合物和方法 - Google Patents

用于治疗或预防与β冠状病毒感染相关的疾病的组合物和方法 Download PDF

Info

Publication number
CN116322662A
CN116322662A CN202180068018.3A CN202180068018A CN116322662A CN 116322662 A CN116322662 A CN 116322662A CN 202180068018 A CN202180068018 A CN 202180068018A CN 116322662 A CN116322662 A CN 116322662A
Authority
CN
China
Prior art keywords
ketotifen
nsaid
subject
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180068018.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·艾沃森
T·A·达奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senjame Pharmaceutical Co ltd
Original Assignee
Senjame Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senjame Pharmaceutical Co ltd filed Critical Senjame Pharmaceutical Co ltd
Publication of CN116322662A publication Critical patent/CN116322662A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180068018.3A 2020-08-06 2021-08-06 用于治疗或预防与β冠状病毒感染相关的疾病的组合物和方法 Pending CN116322662A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063062138P 2020-08-06 2020-08-06
US63/062,138 2020-08-06
PCT/US2021/044897 WO2022032069A1 (en) 2020-08-06 2021-08-06 Compositions and methods for treating or preventing disease associated with beta coronavirus infection

Publications (1)

Publication Number Publication Date
CN116322662A true CN116322662A (zh) 2023-06-23

Family

ID=80117684

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180068018.3A Pending CN116322662A (zh) 2020-08-06 2021-08-06 用于治疗或预防与β冠状病毒感染相关的疾病的组合物和方法

Country Status (10)

Country Link
US (1) US20240033259A1 (https=)
EP (1) EP4192457B1 (https=)
JP (1) JP2023537369A (https=)
KR (1) KR20230048517A (https=)
CN (1) CN116322662A (https=)
AU (1) AU2021321535A1 (https=)
CA (1) CA3188387A1 (https=)
IL (1) IL300406A (https=)
MX (1) MX2023001570A (https=)
WO (1) WO2022032069A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046201A1 (en) 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION
CN116178373B (zh) * 2022-12-06 2024-06-18 南方科技大学 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
US20190060297A1 (en) * 2017-08-30 2019-02-28 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Adverse Effects Associated with Vaccinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
US20190060297A1 (en) * 2017-08-30 2019-02-28 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Adverse Effects Associated with Vaccinations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARLA AMICI ET AL: "Indomethacin has a potent antiviral activity against SARS coronavirus", ANTIVIRAL THERAPY, vol. 11, no. 8, 24 July 2006 (2006-07-24), pages 1021 - 1030, XP055713077 *
PIETRO EMANUELE NAPOLI ET AL: "A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era", JOURNAL OF CLINICAL MEDICINE, 30 July 2020 (2020-07-30), pages 1 - 16 *
VICTOR M. CASTRO MS ET AL: "Brief Report: Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records", MEDRXIV PREPRINT DOI: HTTPS://DOI.ORG/10.1101/2020.04.11.20061994, 2020-4-16, 16 April 2020 (2020-04-16), pages 1 - 16 *

Also Published As

Publication number Publication date
EP4192457A1 (en) 2023-06-14
AU2021321535A1 (en) 2023-03-23
IL300406A (en) 2023-04-01
EP4192457A4 (en) 2024-09-18
MX2023001570A (es) 2023-05-03
WO2022032069A1 (en) 2022-02-10
CA3188387A1 (en) 2022-02-10
KR20230048517A (ko) 2023-04-11
JP2023537369A (ja) 2023-08-31
EP4192457B1 (en) 2026-03-25
US20240033259A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
EP2799071B1 (en) Levocetirizine and montelukast for the treatment of influenza and common cold
ES2263643T3 (es) Uso de hidroxietilrutosidos para el tratamiento de los sintomas del r esfriado comun, de la fiebre de heno y de infecciones relacionadas con el tacto respiratorio.
US20230131929A1 (en) Quinoline compounds for treating respiratory disorders and viral infections
JP6567781B2 (ja) ウイルス感染症の治療用チアゾリド化合物
US20180185404A1 (en) Compositions and methods for the treatment of viral infection
WO2021217702A1 (zh) 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用
CN117695284A (zh) 冠状病毒感染的治疗
CN116322662A (zh) 用于治疗或预防与β冠状病毒感染相关的疾病的组合物和方法
US20240115559A1 (en) Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
RU2237475C1 (ru) Комбинированный препарат для устранения симптомов простудных заболеваний и гриппа (варианты)
CN115697342A (zh) 用于治疗病毒感染的化合物
EP2558097B1 (en) Vapendavir for the alleviation of symptoms of asthma in a subject having a HRV infection
US10045984B2 (en) Combination therapy
US20220040228A1 (en) Materials and methods for stopping respiratory virus infections
EP4181887A1 (en) Pde3 inhibitors for treating viral infections
CN117838689A (zh) 培菲替尼在制备治疗流感病毒感染的药物中的应用
WO2022030616A1 (ja) コロナウイルスによる感染症治療用の医薬組成物
JP2019104684A (ja) Ａｇｒ２発現促進剤
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold
JPH11116501A (ja) 骨吸収関連疾患治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination